Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Julie A. Stone(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yusheng Wu, Sarah W. Li, Eric J. Gilbert, Eric M. Parker(University of New Hampshire), Andrew P. J. Brunskill, Ganfeng Wang, Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), William J. Greenlee, Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Orth, Irina Kazakevich, Kathleen Cox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lana M. Rossiter(Albany Molecular Research (United States)), Jared N. Cumming(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey Misiaszek, Meagan Slater(Albany Molecular Research (United States)), Johannes Voigt, Robert A. Hodgson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xia Chen(First People's Hospital of Foshan), Hongwu Wang(Meitan General Hospital), Qin Jiang(Nanjing Medical University), Corey O. Strickland, J. Wayne Meredith, Mark S. Forman, Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ulrich Iserloh
Journal of Medicinal Chemistry
November 18, 2016
Cited by 165


Related Papers